Search: WFRF:(Hjertner Oyvind)
> (2013) >
Bortezomib consolid...
Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial
-
- Mellqvist, Ulf-Henrik (author)
- Sahlgrens University Hospital, Sweden
-
- Gimsing, Peter (author)
- Rigshosp, Denmark
-
- Hjertner, Oyvind (author)
- Norwegian University of Science and Technology, Norway
-
show more...
-
- Lenhoff, Stig (author)
- Lund University,Lunds universitet,Avdelningen för hematologi och transfusionsmedicin,Institutionen för laboratoriemedicin,Medicinska fakulteten,Division of Hematology and Transfusion Medicine,Department of Laboratory Medicine,Faculty of Medicine,Skåne University Hospital, Sweden
-
- Laane, Edward (author)
- North Estonian Regional Hospital, Estonia
-
- Remes, Kari (author)
- Turku University, Finland
-
- Steingrimsdottir, Hlif (author)
- Landspitali University Hospital, Iceland
-
- Abildgaard, Niels (author)
- Odense University Hospital, Denmark
-
- Ahlberg, Lucia (author)
- Östergötlands Läns Landsting,Linköpings universitet,Onkologi,Hälsouniversitetet,Hematologiska kliniken US
-
- Blimark, Cecilie (author)
- Sahlgrens University Hospital, Sweden
-
- Dahl, Inger Marie (author)
- University of North Norway, Norway
-
- Forsberg, Karin (author)
- Umeå universitet,Patologi,Norrlands University Hospital, Sweden
-
- Gedde-Dahl, Tobias (author)
- Oslo University Hospital, Norway
-
- Gregersen, Henrik (author)
- Aalborg Hospital, Denmark
-
- Gruber, Astrid (author)
- Karolinska Institute, Sweden
-
- Guldbrandsen, Nina (author)
- Oslo University Hospital, Norway
-
- Haukas, Einar (author)
- Stavanger University Hospital, Norway
-
- Carlson, Kristina (author)
- Uppsala universitet,Hematologi,Akad University Hospital, Sweden
-
- Kvam, Ann Kristin (author)
- Oslo University Hospital, Norway
-
- Nahi, Hareth (author)
- Karolinska Institutet,Karolinska Institute, Sweden
-
- Lindas, Roald (author)
- Haukeland Hospital, Norway
-
- Frost Andersen, Niels (author)
- Aarhus University Hospital, Denmark
-
- Turesson, Ingemar (author)
- Lund University,Lunds universitet,Avdelningen för hematologi och transfusionsmedicin,Institutionen för laboratoriemedicin,Medicinska fakulteten,Division of Hematology and Transfusion Medicine,Department of Laboratory Medicine,Faculty of Medicine,Skåne University Hospital, Sweden
-
- Waage, Anders (author)
- Norwegian University of Science and Technology, Norway
-
- Westin, Jan (author)
- Sahlgrens University Hospital, Sweden
-
show less...
-
(creator_code:org_t)
- American Society of Hematology, 2013
- 2013
- English.
-
In: Blood. - : American Society of Hematology. - 0006-4971 .- 1528-0020. ; 121:23, s. 4647-4654
- Related links:
-
https://ashpublicati...
-
show more...
-
http://dx.doi.org/10... (free)
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
https://lup.lub.lu.s...
-
https://urn.kb.se/re...
-
http://kipublication...
-
https://urn.kb.se/re...
-
show less...
Abstract
Subject headings
Close
- The Nordic Myeloma Study Group conducted an open randomized trial to compare bortezomib as consolidation therapy given after high-dose therapy and autologous stem cell transplantation (ASCT) with no consolidation in bortezomib-naive patients with newly diagnosed multiple myeloma. Overall, 370 patients were centrally randomly assigned 3 months after ASCT to receive 20 doses of bortezomib given during 21 weeks or no consolidation. The hypothesis was that consolidation therapy would prolong progression-free survival (PFS). The PFS after randomization was 27 months for the bortezomib group compared with 20 months for the control group (P = .05). Fifty-one of 90 patients in the treatment group compared with 32 of 90 controls improved their response after randomization (P = .007). No difference in overall survival was seen. Fatigue was reported more commonly by the bortezomib-treated patients in self-reported quality-of-life (QOL) questionnaires, whereas no other major differences in QOL were recorded between the groups. Consolidation therapy seemed to be beneficial for patients not achieving at least a very good partial response (VGPR) but not for patients in the andgt;= VGPR category at randomization. Consolidation with bortezomib after ASCT in bortezomib-naive patients improves PFS without interfering with QOL. This trial was registered at www.clinicaltrials.gov as #NCT00417911.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Hematologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Hematology (hsv//eng)
Keyword
- MEDICINE
- MEDICIN
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
-
Blood
(Search for host publication in LIBRIS)
To the university's database
- By the author/editor
-
Mellqvist, Ulf-H ...
-
Gimsing, Peter
-
Hjertner, Oyvind
-
Lenhoff, Stig
-
Laane, Edward
-
Remes, Kari
-
show more...
-
Steingrimsdottir ...
-
Abildgaard, Niel ...
-
Ahlberg, Lucia
-
Blimark, Cecilie
-
Dahl, Inger Mari ...
-
Forsberg, Karin
-
Gedde-Dahl, Tobi ...
-
Gregersen, Henri ...
-
Gruber, Astrid
-
Guldbrandsen, Ni ...
-
Haukas, Einar
-
Carlson, Kristin ...
-
Kvam, Ann Kristi ...
-
Nahi, Hareth
-
Lindas, Roald
-
Frost Andersen, ...
-
Turesson, Ingema ...
-
Waage, Anders
-
Westin, Jan
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Hematology
- Articles in the publication
-
Blood
- By the university
-
Linköping University
-
Lund University
-
Uppsala University
-
Karolinska Institutet
-
Umeå University